TFF Pharmaceuticals
OverviewSuggest Edit
TFF Pharmaceuticals is a biopharmaceutical company focused on developing drug products based on the Thin Film Freezing (TFF) technology platform. It develops inhalation drug products to treat chronic respiratory diseases and lung conditions. The company generates dry powder inhaler version of drugs.
| Type | Public | |
| Founded | 2018 | |
| HQ | Austin, TX, US | Map |
| Website | tffpharma.com |
Recent NewsAll News
- TFF Pharmaceuticals to Hold Second Quarter 2021 Financial and Business Results Conference Call on August 12, 2021
- Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387
- TFF Pharmaceuticals to Participate in the BTIG Virtual Biotechnology Conference
- TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical Trial of Tacrolimus Inhalation Powder
Key People/Management at TFF Pharmaceuticals
Brian Windsor
Director & CSO
Glenn Mattes
President, Chief Executive Officer and Director
Kirk Coleman
Chief Financial Officer
Aaron Fletcher
Chairman of the Board
Stephen Rocamboli
Director
Robert S. Mills
Director
TFF Pharmaceuticals Office Locations
TFF Pharmaceuticals has an office in Austin
Austin, TX, US (HQ)
2600 Vía Fortuna #360
TFF Pharmaceuticals Financials and Metrics
TFF Pharmaceuticals Revenue
| USD | |
|---|---|
Net income (FY, 2020) | (18.6m) |
EBIT (FY, 2020) | (18.7m) |
Market capitalization (3-Aug-2021) | 210.0m |
Closing stock price (3-Aug-2021) | 8.3 |
Cash (31-Dec-2020) | 35.3m |
TFF Pharmaceuticals's current market capitalization is $210 m.
Annual
Annual
Quarterly
TFF Pharmaceuticals Cybersecurity Score
TFF Pharmaceuticals Online and Social Media Presence
TFF Pharmaceuticals's Trends
TFF Pharmaceuticals News and Updates
August 04, 2021
TFF Pharmaceuticals to Hold Second Quarter 2021 Financial and Business Results Conference Call on August 12, 2021
Company conference call and webcast at 4:30 PM EDT Company conference call and webcast at 4:30 PM EDT
July 29, 2021
Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387
Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays
July 28, 2021
TFF Pharmaceuticals to Participate in the BTIG Virtual Biotechnology Conference
AUSTIN, Texas, July 28, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that its Pres…
July 13, 2021
TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical Trial of Tacrolimus Inhalation Powder
Inhaled Tacrolimus Powder Achieves Systemic Therapeutic Drug Levels Anticipate Additional Safety Data in 3Q 2021 Initiation of Lung Transplant Study Expected in 2H 2021
June 22, 2021
Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clinical Development Against COVID-19
AUG-3387 Active Against All Variants Tested Including the UK (B.1.1.7), South African (B.1.351), Indian (B.1.617.1), and Brazil (P.1) Variants AUG-3387 Active Against All Variants Tested Including the UK (B.1.1.7), South African (B.1.351), Indian (B.1.617.1), and Brazil (P.1) Variants
June 07, 2021
TFF Pharmaceuticals Hosting Key Opinion Leader Perspectives on Thin Film Freezing Applications
Focus on TFF Tacrolimus for Lung Transplant and TFF in Vaccine Technology
TFF Pharmaceuticals Blogs
May 13, 2021
TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
Content Import
Thu, 05/13/2021 - 16:00
TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
May 13, 2021 at 4:00 PM EDT
This …
May 04, 2021
TFF Pharmaceuticals to Hold First Quarter 2021 Financial and Business Results Conference Call on May 13, 2021
Company conference call and webcast at 4:30 PM EDT AUSTIN, Texas --(BUSINESS WIRE)--May 4, 2021-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF)
April 13, 2021
TFF Pharmaceuticals Awarded Contract under DARPA’s Next-Generation Personalized Protective Biosystems Program for U.S. Warfighters
Company’s Thin Film Freezing platform to be developed for use in rapidly neutralizing chemical and biological threats at vulnerable tissue barriers to increase soldier protection and decrease operational burden AUSTIN, Texas --(BUSINESS WIRE)--Apr. 13, 2021-- TFF Pharmaceuticals, Inc.
March 26, 2021
TFF Pharmaceuticals Prices Offering of Common Stock
TFF Pharmaceuticals Prices Offering of Common Stock
Content Import
Fri, 03/26/2021 - 08:30
TFF Pharmaceuticals Prices Offering of Common Stock
March 26, 2021 at 8:30 AM EDT
This release is a backfill from a News Wire
General
AUSTI…
March 10, 2021
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results
Content Import
Wed, 03/10/2021 - 16:00
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results
March 10, 2021 at 4:00 PM EST
This …
March 09, 2021
NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration
Feasibility work underway to determine the compatibility of NeuroRx’s ZYESAMI™ (aviptadil, synthetic VIP) as a dry powder formulation using TFF’s Thin-Film Freezing technology Dry powder inhalation technology has the potential to deliver ZYESAMI directly to the lungs RADNOR, Pa.
TFF Pharmaceuticals Frequently Asked Questions
When was TFF Pharmaceuticals founded?
TFF Pharmaceuticals was founded in 2018.
Who are TFF Pharmaceuticals key executives?
TFF Pharmaceuticals's key executives are Brian Windsor, Glenn Mattes and Kirk Coleman.
How many employees does TFF Pharmaceuticals have?
TFF Pharmaceuticals has 4 employees.
Who are TFF Pharmaceuticals competitors?
Competitors of TFF Pharmaceuticals include Nuvaira, Gentex Pharma and Lung Therapeutics.
Where is TFF Pharmaceuticals headquarters?
TFF Pharmaceuticals headquarters is located at 2600 Vía Fortuna #360, Austin.
Where are TFF Pharmaceuticals offices?
TFF Pharmaceuticals has an office in Austin.
How many offices does TFF Pharmaceuticals have?
TFF Pharmaceuticals has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies